205 related articles for article (PubMed ID: 34796373)
1. Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France.
Garin E; Pinaquy JB; Bailly C; Sengel C; Mariano-Goulart D; Edeline J; Blanc JF; Bouvier A; Tordo J; Rode A; Becker S; Sefrioui D; de Baere T; Somma C; Mastier C; Goupil J; Chevallier P; Regnault H; Vibert E; Manfredi S; Vicaut E; Patel B; Boucher E; Guiu B;
Cardiovasc Intervent Radiol; 2022 Jan; 45(1):1-11. PubMed ID: 34796373
[TBL] [Abstract][Full Text] [Related]
2. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
4.
Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
[TBL] [Abstract][Full Text] [Related]
5. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
[TBL] [Abstract][Full Text] [Related]
6. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
7. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
8. Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.
Lewandowski RJ; Minocha J; Memon K; Riaz A; Gates VL; Ryu RK; Sato KT; Omary R; Salem R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):486-93. PubMed ID: 24114004
[TBL] [Abstract][Full Text] [Related]
9. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E; Tselikas L; Guiu B; Chalaye J; Edeline J; de Baere T; Assenat E; Tacher V; Robert C; Terroir-Cassou-Mounat M; Mariano-Goulart D; Amaddeo G; Palard X; Hollebecque A; Kafrouni M; Regnault H; Boudjema K; Grimaldi S; Fourcade M; Kobeiter H; Vibert E; Le Sourd S; Piron L; Sommacale D; Laffont S; Campillo-Gimenez B; Rolland Y;
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):17-29. PubMed ID: 33166497
[TBL] [Abstract][Full Text] [Related]
10. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience.
Yu Q; Patel M; Kwak D; Ungchusri E; Wang Y; Van Ha T; Zangan S; Marshall E; Little K; Baker T; Liao CY; Pillai A; Ahmed O
J Vasc Interv Radiol; 2023 Nov; 34(11):1970-1976.e1. PubMed ID: 37532096
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
Rafi S; Piduru SM; El-Rayes B; Kauh JS; Kooby DA; Sarmiento JM; Kim HS
Cardiovasc Intervent Radiol; 2013 Apr; 36(2):440-8. PubMed ID: 22956045
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
[TBL] [Abstract][Full Text] [Related]
14. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Weber M; Lam M; Chiesa C; Konijnenberg M; Cremonesi M; Flamen P; Gnesin S; Bodei L; Kracmerova T; Luster M; Garin E; Herrmann K
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1682-1699. PubMed ID: 35146577
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
Lee EW; Alanis L; Cho SK; Saab S
Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
17. Radiation Segmentectomy for the Treatment of Primary Hepatic Malignancies of the Caudate Lobe: A Case Series.
Arora M; Toskich BB; Lewis AR; Padula CA; Montazeri SA; Ritchie C; Frey G; Paz-Fumagalli R; McKinney JM; Devcic Z
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1485-1493. PubMed ID: 36028573
[TBL] [Abstract][Full Text] [Related]
18. Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease.
Padia SA
Tech Vasc Interv Radiol; 2019 Jun; 22(2):81-86. PubMed ID: 31079715
[TBL] [Abstract][Full Text] [Related]
19. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.
Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
Wagemans MEHM; Kunnen B; Stella M; van Rooij R; Smits M; Bruijnen R; Lam MGEH; de Jong HWAM; Braat AJAT
J Nucl Med; 2024 Feb; 65(2):272-278. PubMed ID: 38176716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
